Surrey Heartlands

Joint Formulary & PAD

Somatrogon - Growth failure - children

You are here : Home > Formulary Search > Somatrogon - Growth failure - children

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
ICB
NICE
Restrictions / Comments :
Documents :
 
Shared Care
Paediatric growth hormone shared care document Jun24.pdf

Documentation

Shared Care
Shared Care Request letter (Specialist to Primary Care Prescriber) - National Shared Care - Appendix 1
Shared Care
Shared Care Agreement Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 2
Shared Care
Shared Care Refusal Letter (Primary Care Prescriber to Specialist)- National Shared Care - Appendix 3
Evidence Review
Somatrogon for growth disturbance in children and young people - NICE briefing paper - March 2023.pdf
Webpage
NICE TA863 - Somatrogon for growth disturbance in children and young people - March 2023

PAD Profile

ChemicalSubstance :
Somatrogon
Indication :
Growth failure - children
Group Name :
Keywords :
Growth failure, shared care, NICE
Brand Names Include :
Ngenla
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
6

Other Indications

Below are listed other indications that Somatrogon is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Growth failure - children.

Committee Recommendations (2)

07 Aug 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

.The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the reviewed AMBER shared care document for Recombinant human growth hormone for children and young people.

01 Mar 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends somatrogon as a treatment option for the treatment of growth disturbance caused by growth hormone deficiency in children and young people aged 3 years and over in line with NICE TA863

Somatrogon will be considered AMBER on the traffic light system 

Patients should not be referred for a switch to somatrogon from other growth hormone preparations but can consider switch on discussion with the specialist team at their next routine follow up appointment.